Cost-Effectiveness Model Conceptualisation in Chronic Graft Versus Host Disease

Author(s)

Lew E1, Abdul Jabbar OA2, Kongnakorn T3, Houisse I4, Hudson R5, Skinner L6, Szabó G4, Prawitz T7, Dobi B4, Nicholls C6
1Sanofi, Paris, 75, France, 2Sanofi, Milan, Italy, 3Evidera, Bangkok, Thailand, 4Evidera, Budapest, Hungary, 5Sanofi, Reading, RDG, UK, 6Sanofi, Reading, UK, 7Evidera, Paris, France

OBJECTIVES: Failure-free survival (FFS) in chronic graft versus host disease (cGVHD) is a single, clinically recognised composite end point defined as the absence of treatment change, the absence of underlying malignancy and non-relapse mortality. This study describes an economic analysis model that utilises FFS data to estimate the mean costs and benefits of cGVHD treatments.

METHODS: A partitioned survival model with a 4-week cycle and three health states (failure-free [FF], failure and death) was developed in Microsoft ExcelÒ to estimate the clinical and economic outcomes of cGVHD treatments over a lifetime horizon. Patients enter the model in the FF state and may transition to the failure state after experiencing a recurrence of their malignancy or the initiation of a new cGVHD systemic therapy. Patients may transition to the death state either from the FF or the failure state. The model is populated by FFS and overall survival curves for each treatment and offers the flexibility to account or not account for response status (complete response, partial response or a lack of response) within the FF state using time to response and duration of response data. Health-related quality of life (HRQoL) associated with these health states and the impact on caregivers’ HRQoL were also assessed and incorporated into the model.

RESULTS: The model was populated with data from pooled analyses of the ROCKstar and Phase 2a clinical trials for belumosudil and the REACH3 trial for best available therapy (BAT) for cGVHD and estimated lifetime clinical outcomes. The life years and quality-adjusted life years (discounted at 3.5% per annum) were 6.77 and 3.58 for belumosudil versus 5.52 and 2.10 with BAT, respectively.

CONCLUSIONS: Modelling FFS outcomes is a clinically and payer-relevant approach to cost-effectiveness analysis, which captures the patient journey and value of cGVHD treatments.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)

Code

MSR149

Topic

Methodological & Statistical Research

Disease

Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×